Skip to main content
Timmy Lee, MD, Nephrology, Birmingham, AL, University of Alabama Hospital

TimmyLeeMD

Nephrology Birmingham, AL

Chronic Renal Failure & Dialysis, Hypertension, Interventional Nephrology

Professor of Medicine, University of Alabama at Birmingham; Section Chief, Nephrology, Birmingham Veterans Affairs Medical Center

Dr. Lee is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Lee's full profile

Already have an account?

Education & Training

  • University of Alabama Medical Center
    University of Alabama Medical CenterFellowship, Nephrology, 2004 - 2007
  • University of Alabama Medical Center
    University of Alabama Medical CenterResidency, Internal Medicine, 2001 - 2004
  • LSU School of Medicine in Shreveport
    LSU School of Medicine in ShreveportClass of 2001
  • Washington University in St. Louis
    Washington University in St. LouisB.A., Chemistry, Cum Laude, 1993 - 1997

Certifications & Licensure

  • AL State Medical License
    AL State Medical License 2003 - 2024
  • OH State Medical License
    OH State Medical License 2007 - 2014
  • IN State Medical License
    IN State Medical License 2007 - 2013
  • American Board of Internal Medicine Nephrology

Awards, Honors, & Recognition

  • Carl W. Gottschalk Scholar Grant American Society of Nephrology, 2014
  • Satellite Healthcare Norman S. Coplon Extramural Research Grant 2014
  • Fellow National Kidney Foundation (FNKF), 2012
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • X + Y Scheduling Models for Internal Medicine Residency Programs—A Look Back and a Look Forward  
    Marc Shalaby, Sandra Yaich, John Donnelly, Ryan Chippendale, Maria C. DeOliveira, and Craig Noronha, Journal of Graduate Medical Education, 1/1/2014
  • Canine retina has a primate fovea-like bouquet of cone photoreceptors which is affected by inherited macular degenerations  
    Beltran, W.A., Cideciyan, A.V., Guziewicz, K.E., Iwabe, S., Swider, M., Scott, E.M., Savina, S.V., Ruthel, G., Stefano, F., Zhang, L., Zorger, R., Sumaroka, A., Jacobs..., PLoS One, 1/1/2014
  • Natural history of cone disease in the murine model of Leber congenital amaurosis due to CEP290 mutation: determining the timing and expectation of therapy  
    Boye, S.E., Huang, W.C., Roman, A.J., Sumaroka, A., Boye, S.L., Ryals, R.C., Olivares, M.B., Ruan, Q., Tucker, B.A., Stone, E.M., Swaroop, A., Cideciyan, A.V., Hauswir..., PLoS One, 1/1/2014
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Are Vascular Access Outcomes in the Fistula First Era Affected by the Surgeon?
    Lee T and Allon M, Am J Kidney Dis
  • The outpatient management of ketosis-prone diabetes at Bellevue Hospital.
    Ghosh AK, Osman J, Levy NK, Journal of General Internal Medicine, 1/1/2014
  • Improvement in biomarkers after intrathecal iduronidase for children with MPS IH.
    Lund TC, Miller W, Polgreen L, Baso L, Raymond G, Tolar J, Orchard P, Mol Genet Metabol, 1/1/2014
  • Join now to see all

Lectures

  • Keeping the Bugs Away: Preventing, Diagnosing, and Treating Common Infections in the Dialysis Unit 
    American Society of Nephrology Kidney Week 2019 - Washington, D.C. - 11/8/2019
  • Respiratory Illnesses. 
    1/1/2014
  • The Efficient Clinical Session 
    1/18/2013
  • Join now to see all

Press Mentions

  • Proteon Therapeutics Announces Second Quarter 2018 Financial Results
    Proteon Therapeutics Announces Second Quarter 2018 Financial ResultsAugust 7th, 2018
  • Care Could Improve for Dialysis Patients with Development of Bionanomatrix Gel with $2 Million Grant
    Care Could Improve for Dialysis Patients with Development of Bionanomatrix Gel with $2 Million GrantOctober 5th, 2017
  • Proteon Therapeutics Announces Full-Year 2016 Financial Results and Changes to the Ongoing Phase 3 PATENCY-2 Clinical Trial
    Proteon Therapeutics Announces Full-Year 2016 Financial Results and Changes to the Ongoing Phase 3 PATENCY-2 Clinical TrialMarch 16th, 2017
  • Join now to see all

Professional Memberships

Hospital Affiliations